Company: CMND
Filing Date: 2025-01-22
Form Type: 20-F
Source: 0001213900-25-005490
Chunk: 172

Company: Clearmind Medicine Inc.
Filing Date: 2025-01-22
Form: 20-F
Item: Item 5
Chunk 172
---
6 million net of issuance costs. As of October 31, 2024, we had $6,573,813 in cash.

The table below describes the difference between
our anticipated use of proceeds from public and private offerings completed since November 2022, as disclosed in previous filings with
the SEC. The table shows the amounts actually spent for the period from November 1, 2022, through to October 31, 2024. The variances noted
below do not have a material impact on our ability to achieve our business objectives and milestones. The table below does not include
proceeds received from the exercise of warrants issued in such offerings.

  Use of Available Funds                                                                                                                                                                                    Disclosure        Spent        
                                                                                                                                                                                                            Regarding         through to   
                                                                                                                                                                                                            Use of            October 31,  
                                                                                                                                                                                                            Proceeds          2024         
                                                                                                                                                                                                            (USD)             (USD)        
  November 2022 Public Offering:                                                                                                                                                                                                           
  To advance the formulation and clinical development efforts in our MEAI patented compounds (completed);                                                                                                   1.5 million       1.5 million  
  To complete the pre-IND enabling studies and IND submission (completed)                                                                                                                                   1.0 million       1.0 million  
  To complete planned Phase I/IIa studies                                                                                                                                                                   3.5 million       0.8 million  
  The remainder for working capital and general corporate purposes and possible in-licensing of intellectual property for new product candidates                                                            0.4 million       0.4 million  
  April 2023 Public Offering                                                                                                                                                                                                               
  General corporate purposes, which may include operating expenses, research and development, including clinical and pre-clinical testing of our product candidates, working capital, future acquis...      2.9 million       2.9 million  
  September 2023 Public Offering                                                                                                                                                                                                           
  For general corporate purposes, which may include operating expenses, research and development, including clinical and pre-clinical testing of its product candidates, working capital, future ac...      2.25 million      0.6 million  
  January 2024 Public Offering and Concurrent Private Placement                                                                                                                                                                            
  For general corporate purposes and working capital.                                                                                                                                                       2.4 million       0.6 million  
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

Year Ended October 31, 2024 Compared to